TRIM32 and cancer: The dysregulation of c-Myc in cancer cells promoted TRIM32 expression (Fig. 8D), which ubiquitinated SIRT4 for the proteasome-dependent degradation, thereby facilitating methionine cycle by reducing the ADP-ribosylation modification of MAT2A (Fig. 8D).